Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for 009-001-C21

MIP-3 beta Human Recombinant Protein

Overview

Description:	MIP-3ß Human Recombinant Protein - 009-001-C21
Item No.:	009-001-C21
Size:	20 µg
Applications:	SDS-PAGE
Origin:	Human
Expressed in:	E. coli

Product Details

Background:	The MIP-3ß (also known as SCYA19) member of the intercrine beta (chemokine CC) family may play a role not only in inflammatory and immunological responses, but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. It is secreted. It specifically binds to chemokine receptor CCR7. MIP3ß is expressed at high levels in the lymph nodes, thymus and appendix, and at intermediate levels seen in colon and trachea, while low levels found in spleen, small intestine, lung, kidney and stomach. Recombinant Human MIP-3b produced in E. coli is a single, non-glycosylated, polypeptide chain containing 77 amino acids and having a molecular mass of 8809 Daltons. The recombinant protein shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes.
Synonyms:	C-C motif chemokine 19, Small-inducible cytokine A19, Macrophage inflammatory protein 3 beta, MIP-3-beta, MIP3B, Epstein-Barr virus-induced molecule 1 ligand chemokine, EBI1 ligand chemokine, ELC, Beta-chemokine exodus-3, CK beta-11, SCYA19
Species of Origin:	Human
Expressed in:	E. coli
Type:	Recombinant Protein
Low Endotoxin:	Yes

Target Details

Gene Name:	CCL19

Purity/Specificity:	Recombinant protein corresponds to amino acids 22 to 98 of mature human MIP-3ß. Purity is greater than 98% as determined by reducing and non-reducing SDS-PAGE and by RP- HPLC, against known standard.
Relevant Links:	• NCBI • UniProtKB - Q99731

Application Details

Tested Applications:	SDS-PAGE
Application Note:	MIP-3ß Recombinant Protein has been tested by SDS-PAGE and is suitable as a control for polyclonal or monoclonal anti-MIP-3ß in immunological assays.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
Other:	Biological Activity: Macrophage Inflammatory Protein 3ß is fully biologically active when compared to standard. The activity is calculated by the ability to chemoattract human T cells using a concentration of 7 - 40 ng/ml. Endotoxin Level: Measured by LAL is <0.01ng/µg or <0.1EU/µg.

Formulation


Physical State:	Lyophilized
Concentration:	0.1 mg/mL by UV absorbance at 280 nm
Buffer:	0.1% Trifluoroacetic acid
Preservative:	None
Stabilizer:	None
Reconstitution Volume:	20µl (20-200µl)
Reconstitution Buffer:	Restore with deionized water (or equivalent)

Shipping & Handling

Shipping Condition:	Ambient

Storage Condition:	Store vial at 4° C prior to restoration. Dilute only prior to immediate use. Maintain sterility. This product DOES NOT contain preservative. DO NOT VORTEX. We recommend adding a carrier protein such as HSA or BSA to 0.1% (i.e. 1.0 mg/mL) . For best results aliquot contents and freeze at -20° C or colder. Avoid cycles of freezing and thawing. Centrifuge vial before each opening to dislodge contents from the cap and to clarify if contents are not clear after standing at room temperature.
Expiration:	Expiration date is six (6) months from date of receipt.

Images



SDS-PAGE
SDS-PAGE shows band corresponding to MIP-3ß (1µg) in lane 1 (unreduced) and lane 3 (reduced, arrowhead). Molecular weight estimation was made by comparison to prestained MW markers, lane 2.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.